GSK's Mosquirix vaccine clears EU hurdle but is no 'complete answer' to malaria
This article was originally published in Scrip
Executive Summary
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended GlaxoSmithKline's partially successful malaria vaccine Mosquirix – also known as RTS,S – be approved in children aged 6 weeks to 17 months.